U-46619 Struktur

U-46619

Bezeichnung:U-46619

CAS-Nr56985-40-1

Englisch Name:U-46619

CBNumberCB6437516

SummenformelC21H34O4

Molgewicht350.49

MOL-Datei56985-40-1.mol

U-46619 physikalisch-chemischer Eigenschaften

Siedepunkt	519.7±30.0 °C(Predicted)
Dichte	1.092±0.06 g/cm3(Predicted)
Flammpunkt	-10 °C
storage temp.	-20°C
Löslichkeit	≥100 mg/mL in DMSO, ≥100 mg/mL in Ethanol, ≥100 mg/mL in DMF, ≥2 mg/mL in PBS pH 7.2
pka	4.76±0.10(Predicted)
Aggregatzustand	solution
BRN	4267334

Sicherheit

Kennzeichnung gefährlicher	F,Xi
R-Sätze:	11-36-66-67
S-Sätze:	16-26
RIDADR	UN 1231 3/PG 2
WGK Germany	2
RTECS-Nr.	MJ9681090
F	8-10-23
Toxizität	LD50 intravenous in mouse: 66ug/kg

Gefahreninformationscode (GHS)

U-46619 Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R11:Leichtentzündlich.
R36:Reizt die Augen.
R66:Wiederholter Kontakt kann zu spröder oder rissiger Haut führen.
R67:Dämpfe können Schläfrigkeit und Benommenheit verursachen.
S-Sätze Betriebsanweisung:
S16:Von Zündquellen fernhalten - Nicht rauchen.
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
Verwenden
U 46619 is a PGH2 analog that may be used as a thromboxane A2 (TP) receptor agonist affecting mitogenic growth of vascular smooth muscle in humans.
Biologische Aktivität
PGH 2 (TXA 2 ) analog that is a potent and stable thromboxane A 2 (TP) receptor agonist (EC 50 = 0.035 μ M). Potently stimulates TP receptor-mediated, but not other prostaglandin receptor-mediated responses in various in vitro preparations. Activates ERK-1 and ERK-2 in HEK-293 cells expressing TP α and TP β receptors.
Biochem/physiol Actions
Thromboxane receptor agonist.
in vitro
u46619 showed a biphasic effect on human platelets. shape change and mlcp occurred at low concentrations of this compound (ec50 = 0.035 um and 0.057 um), whereas serotonin release, platelet at higher concentrations (ec50 = 0.536 um and 1.31 um). the effect on platelet shape change and mlcp is receptor mediated [3].
in vivo
u46619, through activation of eta and etb receptors, elicits renal cortical vasoconstriction and medullary vasodilation in the rat [2]. in conscious shr (spontaneously hypertensive rats), 1-100 nmol/kg u-46619 (i.c.v.) induced a dose-related increase in blood pressure but had no significant effect on heart rate [1].
Lager
Store at -20°C
Einzelnachweise
[1] sirén al, svartstrm-fraser m, paakkari i. central cardiovascular effects of the endoperoxide analogue u-46619 in rats. prostaglandins leukot med. 1985 mar; 17 (3): 381-6.
[2] hantz h, adesuyi a, adebayo o. differential effects of u46619 on renal regional hemodynamics in the rat: involvement of endothelin. j pharmacol exp ther. 2001 oct; 299 (1): 372-6.
[3] morinelli ta1, niewiarowski s, daniel jl, smith jb. receptor-mediated effects of a pgh2 analogue (u 46619) on human platelets. am j physiol. 1987 nov; 253 (5 pt 2): h1035-43.

U-46619 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

56985-40-1, U-46619 Verwandte Suche:

Send Inquriy